Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Review examines thoracic radiotherapy combined with chemoimmunotherapy for extensive-stage small cell lung cancer patients
Doctors are still figuring out the best way to treat extensive-stage small cell lung cancer
This review examines the use of thoracic radiotherapy combined with chemoimmunotherapy in patients with extensive-stage small cell lung canc…
A review notes that while combining radiation with chemotherapy and immune therapy helps some patients, the best approach is still being stu…
HS-20093 shows response in lung cancers in Phase 1a/b trial
New Drug Targets Deadly Lung Cancer Cells
A Phase 1a/b trial in 306 patients with previously treated advanced solid tumors found HS-20093, a B7-H3-targeted antibody-drug conjugate, h…
A new drug attacks a specific protein on lung cancer cells, helping more than half of patients with an aggressive type while remaining safe …
Phase II studies evaluate tislelizumab plus sitravatinib or anlotinib maintenance in extensive-stage small-cell lung cancer
Can adding two drugs after chemo help some lung cancer patients survive longer?
These prospective phase II single-arm studies assessed tislelizumab combined with sitravatinib or anlotinib as maintenance therapy in previo…
Adding tislelizumab plus sitravatinib or anlotinib after chemo kept some small-cell lung cancer patients cancer-free for 6.4 to 7.8 months.